Les Echos.fr - February 14, 2011
Sanofi-Aventis intends to make four acquisitions, three in U.S. and one in Israel, in ophthalmology. The deal is worth about one million euro and should be completed over the next three years. The company currently has four molecules in the developing world: in the three more advanced stage (stage II), acquired from the fovea, are allergic conjunctivitis, and the diabetic macular edema. The fourth product, RetinoStat, currently in Phase I, is a gene therapy for macular degeneration, the result of a partnership with Oxford BioMedica. The global market for ophthalmology is estimated to 29 billion dollars.
0 comments:
Post a Comment